This blocks the cell cycle and suppresses cell growth and proliferation (97); it inhibits proteolytic cleavage of the extracellular receptor domain (98); it disrupts interaction between HER2 and SRC tyrosine kinase, inhibiting PTEN activation-mediated cell proliferation (99); it acts as an anti-angiogenic (100); it kills trastuzumab-bound tumour cells by ADCC activation, followed by internalization and degradation of HER2 (101). Here, ERBB2 is linked to neoplasm.